News
GNPX
--
0.00%
--
Live Investor Conference & Webinar: Small and Microcap Company Showcase on February 4th
Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Small and Microcap Showcase. Individual investors, institutional investors, advisors and analysts are invited to attend. The progr...
PR Newswire · 2h ago
BioMedNewsBreaks - Genprex Inc. (NASDAQ: GNPX) CEO to Present at Upcoming Virtual Investor Conference Small and Microcap Showcase
Jan 27, 2021 (Investor Brand Network via COMTEX) -- Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing...
Investor Brand Network · 21h ago
Genprex to Present at the Virtual Investor Conference Small and Microcap Showcase on February 4
Genprex's CEO will present on February 4 at the Virtual Investor Conference.
Business Wire · 1d ago
--Analyst Actions: National Securities Starts Genprex at Buy With $7 Price Target
MT Newswires · 2d ago
Genprex to Present its Cutting-Edge Gene Therapies at the MoneyShow Accredited Investors Virtual Expo
Business Wire · 01/21 13:30
BioMedNewsBreaks - Genprex Inc. (NASDAQ: GNPX) Slated to Present at NobleCon17
Jan 14, 2021 (NetworkNewsWire via COMTEX) -- Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies...
NetworkNewsWire · 01/14 18:19
Genprex to Present at NobleCon17 on January 19
Business Wire · 01/14 13:30
Genprex to Present at NobleCon17 on January 19
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Company will present at the NobleCon17, Noble Cap...
BusinessWire · 01/14 10:30
Genprex achieves manufacturing milestone for immunogene therapy for upcoming lung cancer trials
Genprex ([[GNPX]] +0.4%) has passed the final release tests of scaled-up clinical grade production to supply REQORSA immunogene therapy for upcoming Acclaim-1 and Acclaim-2 trials in non-small cell lung cancer.The company recently announced the completion
Seekingalpha · 01/13 15:33
Genprex Achieves Major Manufacturing Milestone for REQORSA Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer
Genprex Successfully Completes Manufacturing for REQORSA and Passes All Testing
Business Wire · 01/13 14:00
Genprex Achieves Major Manufacturing Milestone for REQORSA(TM) Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer
Genprex, Inc. ("Genprex" or the "Company") (Nasdaq: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced today that it has met all specifications and passed all of the f...
BusinessWire · 01/13 11:00
Genprex's Leading Drug Candidate Is Currently Being Developed As A Treatment For Lung Cancer
Genprex was one of the sponsors for the Benzinga Global Small Cap Conference that took place on December 8-9, 2020.
Benzinga · 12/29/2020 15:18
Genprex, Inc. Announces Closing Of $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Without Warrants
Genprex announces $12 million registered direct closing.
Business Wire · 12/24/2020 18:02
BABA, FUBO, GEVO and NLTX among midday movers
Gainers: Air T (AIRT) +156%.FAT Brands (FAT) +85%.Addex Therapeutics (ADXN) +72%.Senseonics Holdings (SENS) +57%.SIFCO Industries (SIF) +45%.Gevo (GEVO) +44%.Neoleukin Therapeutics (NLTX) +42%.Avinger (AVGR) +41%.IZEA Worldwide (IZEA) +23%.Harvest Capital Credit (HCAP)
Seekingalpha · 12/24/2020 16:17
Genprex, Inc. Announces Closing Of $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Without Warrants
Genprex, Inc. (Nasdaq: GNPX) ("Genprex" or the "Company"), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the closing of its previously announced registered direct ...
BusinessWire · 12/24/2020 15:02
Let's Look at the Big Picture of Genprex
After GNPX's private placement on Tuesday, I spoke with the CEO, Rodney Varner. Here's what I found out and what my views are on the developer of cancer and diabetes therapies....GNPX
TheStreet.com · 12/23/2020 17:40
SUPN, CLNE, MGNI and LIZI among premarket gainers
Lizhi (LIZI) +29%.Ekso Bionics Holdings (EKSO) +25%.AgEagle Aerial Systems (UAVS) +22%.ENGlobal Corporation (ENG) +23%.Supernus Pharmaceuticals (SUPN) +23%.Scopus BioPharma (SCPS) +21%.Mogo (MOGO) +18%.Magnite (MGNI) +18%.Kopin Corporation (KOPN) +18%.Magna International (MGA) +18%.InMed
Seekingalpha · 12/23/2020 13:43
Genprex launches $12M ATM equity offering
Genprex ([[GNPX]] +11.1%) inks agreement with a single healthcare-dedicated institutional investor for the purchase and sale of ~3.12M shares at a purchase price of $3.85/share in a registered direct offering priced at-the-market.No
Seekingalpha · 12/22/2020 18:57
Genprex completes manufacturing scale-up of lung cancer therapy
The clinical-stage micro-cap, Genprex (GNPX), is up +13.6% after the company announced the completion of manufacturing scale-up for its lead product candidate, REQORSA™ immunogene therapy targeting non-small cell lung cancer.Subject to passing final
Seekingalpha · 12/22/2020 18:30
Genprex, Inc. Announces $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules, Without Warrants
Genprex, Inc. (Nasdaq: GNPX) ("Genprex" or the "Company"), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into a securities purchase agreement with a...
Business Wire · 12/22/2020 18:15
Webull provides a variety of real-time GNPX stock news. You can receive the latest news about Genprex Inc through multiple platforms. This information may help you make smarter investment decisions.
About GNPX
Genprex, Inc. is a clinical-stage gene therapy company. The Company is focused on developing cancer-based upon its novel technology platform, including its initial product candidate, Oncoprex, immunogene therapy, or Oncoprex. Oncoprex consists of a tumor suppressor gene inserted into a patient’s cells that has immunomodulatory effects and is thereby considered an immunogene therapy. The gene is one of a series of genes whose therapeutic use is covered by a license from The University of Texas MD Anderson Cancer Center (MD Anderson). It is also developing a pre-clinical gene therapy that is covered by a license from the University of Pittsburgh of the Commonwealth System of Higher Education that has the potential to cure type 1 and type 2 diabetes. It is developing its product candidate to be administered with targeted therapies and with immunotherapies for non-small cell lung cancer (NSCLC).